Move to the main content
:::
劉軒

Hsuan Liu

JobTitle: Professor

CurrentJob: Chang Chung University

E-mail: liu-hsuan@mail.cgu.edu.tw

Phone: 3526

Education: Ph.D., National Taiwan University

Expertise: Cancer Biology; Biomarkers; Omics/Multi-omics or Systems Biology

Research Directions and Laboratory Features

High-throughput biological experimental technologies marked the beginning of the post-genomic era. In recent years, the rapid and explosive development of next-generation sequencing technologies has further advanced biological experimentation toward greater efficiency, precision, and accuracy, creating excellent opportunities for life science research.

Next-generation sequencing, or NGS, is now widely applied in various fields of life science research. Researchers can perform high-speed sequencing of DNA and RNA and, together with downstream bioinformatics applications, investigate genetic sequence variations, structural abnormalities, differential gene expression, small RNA expression, and epigenetic modifications of the genome.

Our laboratory focuses on establishing and applying various next-generation sequencing technology platforms to cancer genomics and transcriptomics research. By integrating bioinformatics analyses, we systematically identify important biological signatures and related pathological features of cancer. Through large-scale database computation, we construct possible regulatory networks involved in cancer development and further use cellular and animal models to conduct in-depth investigations and validation of molecular mechanisms.

In recent years, our major research topics have included the following:


Establishment of a Functional Genomics Database for Taiwanese Cancer Tissues

We aim to establish a comprehensive functional genomics database of Taiwanese cancer tissues, including oral cancer, esophageal cancer, colorectal cancer, and brain cancer. By using bioinformatics approaches and integrating international large-scale databases, we systematically analyze and identify important molecules associated with clinical early diagnosis, disease treatment and medication, drug resistance, survival rate, and recurrence.

We also seek to comprehensively characterize the pathological mechanisms and regulatory networks of these variants. For important mutated genes identified through these analyses, we further use cellular and animal models to investigate and validate the molecular mechanisms of these cancer-related targets.


Development of Bioinformatics Tools for Analyzing Non-coding RNA Regulatory Networks

Based on the known biological characteristics of non-coding RNAs, including long non-coding RNAs, circular RNAs, and microRNAs, we integrate large-scale databases to develop a bioinformatics analysis platform for studying non-coding RNA regulatory networks.

Furthermore, by combining cellular and animal models, we validate the molecular regulatory mechanisms of novel non-coding RNAs identified through these analyses.


Development of Next-Generation Sequencing Applications for Cancer Liquid Biopsy Samples

The composition of exosomes not only reflects their cells of origin but is also enriched with biomolecules related to cellular transformation. Therefore, exosomes have become one of the most promising targets in liquid biopsy approaches in recent years.

Our laboratory has developed a method that requires only 1 cc of plasma to rapidly extract exosomal RNA. Using next-generation sequencing, we have validated that this method significantly optimizes and improves the stability of sample preparation.

We have further established comprehensive exosomal microRNA omics databases from healthy individuals and patients with various types of cancer, including oral cancer, esophageal cancer, lung cancer, and colorectal cancer. By integrating clinical information, we systematically search for multifaceted biomarkers with potential applications in early detection, long-term monitoring of treatment response, and prognosis prediction.

In response to the needs of precision medicine, we have further developed a rapid detection chip system that can accurately and comprehensively monitor cancer status and treatment progression. Using various bioinformatics tools, we comprehensively characterize the functional roles of exosomal microRNAs in cancer progression and conduct in-depth mechanistic studies using cellular and animal models.

Publication

  1.  Yang YE, Lin YA, Ling LL, Kuo IY, Kuo WT, Liu H, Wang YC. Rab37-mediated OPN secretion
    enriches SPP1+ macrophages through autocrine-paracrine signaling to drive lung tumor progression.
    Oncogenesis. 2026 Jan 14;15(1):4. (IF: 6.4, 50/328 ONCOLOGY)
    2. Liu YH, Chen YT, Chen YC, Chin E, Lai YY, Ma CP, Chang Ian YF, Tan CM, Hsu PT, Lai YH, Tsai
    WS, Yang CY, Yu JS, Hsu HC, Liu H. Functional Dynamic Modulation of Colorectal Cancer Initiation
    and Metastatic Capacity by a Novel MiR-7974 Regulatory Axis. Biomed J. 2025 Nov 28:100934. doi:
    10.1016/j.bj.2025.100934. Online ahead of print (Corresponding author). (IF:4.5, 85/320
    BIOCHEMISTRY & MOLECULAR BIOLOGY)
    3. Sullivan SA, Orosco JC, Callejas-Hernández F, Blow F, Lee H, Ranallo-Benavidez TR, Peters A, Raidal
    SR, Girard YA, Johnson CK, Rogers KH, Gerhold R, Mangelson H, Liachko I, Srivastava H, Chandler
    C, Berenberg D, Bonneau RA, Huang PJ, Yeh YM, Lee CC, Liu H, Chen TW, Tang P, Chiu CH, Schatz
    MC, Carlton JM. Comparative genomics of the parasite Trichomonas vaginalis reveals genes involved in
    spillover from birds to humans. Nat Commun. 2025 Jul 24;16(1):6487. (IF:15.7, 7/136
    MULTIDISCIPLINARY SCIENCES)
    4. Teng W, Ku WT, Lin PT, Chen GT, Chu LJ, Liu H, Lin YC, Lin CY. Baseline serum EV-miR-1-3p as a
    protective factor and biomarker for hepatocellular carcinoma development after HCV eradication. J
    Transl Med. 2025 Jul 1;23(1):722. (IF: 7.5, 20/195 MEDICINE, RESEARCH & EXPERIMENTAL)
    5. Chang HC, Tsai CY, Hsu CL, Tai TS, Cheng ML, Chuang YM, Tang HY, Lin KJ, Chen JJ, Chang SH,
    Ko YC, Chi YW, Liu H, Tan BC, Shen CR, Yang CW, Ho PC, Yang HY. Asparagine deprivation
    enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations. Nat
    Metab. 2025 May;7(5):918-927. (IF: 20.8, 5/193 ENDOCRINOLOGY & METABOLISM)
    6. Wu CS, Li HP, Hsieh CH, Lin YT, Chang IY, Chung AK, Huang Y, Ueng SH, Hsiao YC, Chien KY, Luo
    JD, Chen CH, Liao WC, Hung JL, Yuan SN, OuYang CN, Chiang WF, Chien CY, Chuang HC, Chu LJ,
    Liu H, Yang CY, Robles AI Rodriguez H, Lin HH, Yang HY, Hsueh C, Chang KP, Yu JS, Chang YS.
    Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification
    and personalized treatment strategies. Cancer Lett. 2025 Apr 1; 614:217482. (IF: 10.1, 30/328
    ONCOLOGY)
    7. Tseng YH, Tran TTM, Chang JT, Huang YT, Nguyen AT, Chang IY, Chen YT, Hsieh HW, Juang YL,
    Chang PM, Huang TY, Chang YC, Chen YM*, Liu H*, Huang CF*. Utilizing TP53 hotspot mutations
    as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer. Cell Death
    Discov. 2025 Jan 27;11(1):26. (Corresponding author) (IF: 7.0, 40/204 CELL BIOLOGY)
    8. Chen YT, Tsai HJ, Kan CH, Ma CP, Chen HW, Chang IY, Liu H, Wu CC, Chu WY, Wu YC, Chang KP,
    Yu JS, Tan BC. Noncanonical formation of SNX5 gene-derived circular RNA regulates cancer growth.
    Cell Death Dis. 2024 Aug 18;15(8):599. (IF: 9.6, 29/204 CELL BIOLOGY)
    9. Lei KF, Pai PC, Liu H. Development of a Folding Paper System To Enable the Analysis of Gene Profile
    of Short- and Long-Distance Cancer Cell Migration. ACS Appl Mater Interfaces. 2024 Jul
    31;16(30):38931-38941. (Corresponding author) (IF: 8.2, 83/461 MATERIALS SCIENCE,
    MULTIDISCIPLINARY)
    10. Chuang WY, Chang H, Shih LY, Lin TC, Yeh CJ, Ueng SH, Kuo MC, Kao HW, Liu H, Chang ST, Lee
    CL, Huang KP, Wang TH, Wan YL, Yu JS, Hsueh C, Chuang SS. Identification of CD5/SOX11 double-
    negative pleomorphic mantle cell lymphoma. Virchows Arch. 2024 Aug;485(2):323-334. (IF: 3.1, 26/90
    PATHOLOGY)
    11. Huang SC, Chang IY, Chang CJ, Liu H, Chen KH, Liu TT, Hsieh TY, Chuang HC, Chen CC, Lin IC, Ng
    KF, Huang HY, Chen TC. Association between hepatic angiosarcoma and end-stage renal disease:
    nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. J
    Pathol. 2023 Jun;260(2):165-176. (IF: 5.2, 7/90 PATHOLOGY)
    12. Hsieh CH, Kuan WH, Chang WL, Kuo IY, Liu H, Shieh DB, Liu H, Tan B, Wang YC. Dysregulation of
    SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in
    esophageal squamous cell carcinoma. J Biomed Sci. 2022 Oct 30;29(1):90. (IF: 12.1, 9/195 MEDICINE,
    RESEARCH & EXPERIMENTAL)
    13. Yang CK, Hsu HC, Liu YH, Tsai WS, Ma CP, Chen YT, Tan BC, Lai YY, Chang IY, Yang C, Yang CY,
    Yu JS, Liu H. (2022, Aug). EV-miRome-wide profiling uncovers miR-320c for detecting metastatic
    colorectal cancer and monitoring the therapeutic response. Cell Oncol (Dordr).;45(4):621-638.
    (Corresponding author) (IF: 4.8, 75/328 ONCOLOGY)
    14. Chen YT, Kan CH, Liu H, Liu YH, Wu CC, Kuo YP, Chang IY, Chang KP, Yu JS, Tan BC. Modular
    scaffolding by lncRNA HOXA10-AS promotes oral cancer progression. Cell Death Dis. 2022 Jul
    20;13(7):629. (IF: 9.6, 29/204 CELL BIOLOGY)
    15. Yen WC, Chang IY, Chang KP, Ouyang CN, Liu CR, Tsai TL, Zhang YC, Wang CI, Wang YH, Yu AL,
    Liu H, Wu CC, Chang YS, Yu JS, Yang CY. Genomic and Molecular Signatures of Successful Patient-
    Derived Xenografts for Oral Cavity Squamous Cell Carcinoma. Front Oncol. 2022 Apr 4; 12:792297.
    (IF: 3.3, 123/328 ONCOLOGY)
    16. Chiang SF, Huang HH, Tsai WS, Chin-Ming Tan B, Yang CY, Huang PJ, Yi-Feng Chang I, Lin J, Lu PS,
    Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H. Comprehensive functional genomic
    analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III
    colorectal cancer patients. Biomed J. 2022 Apr;45(2):347-360. (Corresponding author) (IF:4.5, 85/320
    BIOCHEMISTRY & MOLECULAR BIOLOGY)
    17. Lin JH, Peng KY, Kuo YP, Liu H, Tan CB, Lin YF, Chiu HW, Lin YH, Chen YM, Chueh JS, Wu VC.
    Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism. Endocr
    Relat Cancer. 2022 Jan 10;29(2):59-69. (IF: 4.6, 43/193 ENDOCRINOLOGY & METABOLISM)
    18. Chen YT, Hsu HC, Lee YS, Liu H, Tan BC, Chin CY, Chang IY, Yang CY. Longitudinal High-
    Throughput Sequencing of the T-Cell Receptor Repertoire Reveals Dynamic Change and Prognostic
    Significance of Peripheral Blood TCR Diversity in Metastatic Colorectal Cancer During Chemotherapy.
    Front Immunol. 2022 Jan 12;12: 743448. (IF: 5.9, 34/183 IMMUNOLOGY)
    19. Tsai WS, Hung WS, Wang TM, Liu H, Yang CY, Wu SM, Hsu HL, Hsiao YC, Tsai HJ, Tseng CP.
    Circulating tumor cell enumeration for improved screening and disease detection of patients with
    colorectal cancer. Biomed J. 2021 Dec;44(6 Suppl 2):S190-S200. (IF:4.5, 85/320 BIOCHEMISTRY &
    MOLECULAR BIOLOGY)
    20. Tseng MH, Fan WL, Liu H, Yang CY, Ding JJ, Lee HJ, Huang SM, Lin SH, Huang JL. Complement
    Factor I Mutation May Contribute to Development of Thrombotic Microangiopathy in Lupus Nephritis.
    Front Med (Lausanne). 2021 Feb 5;7: 621609. (IF: 3.0, 61/332 MEDICINE, GENERAL & INTERNAL)
    21. Wu VC, Peng KY, Kuo YP, Liu H, Tan BC, Lin YH, Lai TS, Chen YM, Chueh JS. TAIPAI. Subtypes of
    Histopathologically Classical Aldosterone-Producing Adenomas Yield Various Transcriptomic Signaling
    and Outcomes. Hypertension. 2021 Dec;78(6):1791-1800. (IF: 8.2, 8/98 PERIPHERAL VASCULAR
    DISEASE)
    22. Chen YT, Chang IY, Kan CH, Liu YH, Kuo YP, Tseng HH, Chen HC, Liu H, Chang YS, Yu JS, Chang
    KP, Tan BC. circRNAome Profiling in Oral Carcinoma Unveils a Novel circFLNB that Mediates Tumour
    Growth-Regulating Transcriptional Response. Cells. 2020 Aug 10;9(8):1868. doi: 10.3390/cells9081868.
    23. Yang CY, Liu CR, Chang IY, OuYang CN, Hsieh CH, Huang YL, Wang CI, Jan FW, Wang WL, Tsai TL,
    Liu H, Tseng CP, Chang YS, Wu CC, Chang KP. Cotargeting CHK1 and PI3K Synergistically
    Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
    Cancers (Basel). 2020 Jun 29;12(7):1726. doi: 10.3390/cancers12071726. IF: 6.575, RANK: 60/245
    ONCOLOGY.
    24. Wu SM, Tsai WS, Chiang SF, Lai YH, Ma CP, Wang JH, Lin J, Lu PS, Yang CY, Tan BC, Liu H.
    Comprehensive transcriptome profiling of Taiwanese colorectal cancer implicates an ethnic basis for
    pathogenesis. Sci Rep. 2020 Mar 11;10(1):4526. doi: 10.1038/s41598-020-61273-y. IF: 4.997, RANK:
    19/74 MULTIDISCIPLINARY SCIENCES. (Corresponding author)
    25. Kuo YP, Ma CP, Chen HW, Chen YT, Lai YH, Liu H, Kuo RL, Chin-Ming Tan B. A novel antisense
    RNA ASPACT confers multi-level suppression of PACT and associated signalling. RNA Biol. 2019
    Sep;16(9):1263-1274. doi: 10.1080/15476286.2019.1624471. Epub 2019 Jun 12. IF: 4.766, RANK:
    120/297 BIOCHEMISTRY & MOLECULAR BIOLOGY.
    26. Chung AK, OuYang CN, Liu H, Chao M, Luo JD, Lee CY, Lu YJ, Chung IC, Chen LC, Wu SM, Tsang
    NM, Chang KP, Hsu CL, Li HP, Chang YS. Targeted sequencing of cancer-related genes in
    nasopharyngeal carcinoma identifies mutations in the TGF-beta pathway. Cancer Med. 2019
    Sep;8(11):5116-5127.
    27. Ma CP, Liu H, Yi-Feng Chang I, Wang WC, Chen YT, Wu SM, Chen HW, Kuo YP, Shih CT, Li CY, Tan
    BC. ADAR1 promotes robust hypoxia signaling via distinct regulation of multiple HIF-1alpha-inhibiting
    factors. EMBO Rep. 2019 May;20(5): e47107.
    28. You GR, Cheng AJ, Lee LY, Huang YC, Liu H, Chen YJ, Chang JT. Prognostic signature associated
    with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses. BMC
    Cancer. 2019 Jan 14;19(1):64.
    29. Lai CY*, Liu H*, Tin KX, Huang Y, Yeh KH, Peng HW, Chen HD, He JY, Chiang YJ, Liu CS, Weng
    SY, Tao MH, Yen JJ, Yang-Yen HF. Identification of UAP1L1 as a critical factor for protein O-
    GlcNAcylation and cell proliferation in human hepatoma cells. Oncogene. 2019 Jan;38(3):317-331.
    (First author) (IF: 7.3, 39/320 BIOCHEMISTRY & MOLECULAR BIOLOGY)
    30. Huang YW, Chiang MF, Ho CS, Hung PL, Hsu MH, Lee TH, Chu LJ, Liu H, Tang P, Victor Ng W, Lin
    DS. A Transcriptome Study of Progeroid Neurocutaneous Syndrome Reveals POSTN As a New Element
    in Proline Metabolic Disorder. Aging Dis. 2018 Dec 4;9(6):1043-1057.
    31. Chao A, Lin CY, Wu RC, Lee YS, Lee LY, Tsai CL, Yang LY, Liu H, Chen SJ, Wang TH, Lai CH. The
    combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial
    cancer: molecular role of insulin-like growth factor binding protein 2. J Mol Med (Berl). 2018
    Nov;96(11):1251-1266.
    32. Chang S, Bok P, Tsai CY, Sun CP, Liu H, Deussing JM, Huang GJ. NPTX2 is a key component in the
    regulation of anxiety. Neuropsychopharmacology. 2018 Aug;43(9):1943-1953.
    33. Chen YT, Chang IY, Liu H, Ma CP, Kuo YP, Shih CT, Shih YH, Kang L, Tan BC. Tumor-associated
    intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferation. J Biol Chem.
    2018 Jun 29;293(26):10158-10171.
    34. Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP, Chang
    YL. Oral Microbiota Community Dynamics Associated with Oral Squamous Cell Carcinoma Staging.
    Front Microbiol. 2018 May 3;9: 862.
    35. Tsai KW, Lo YH, Liu H, Yeh CY, Chen YZ, Hsu CW, Chen WS, Wang JH. Linc00659, a long
    noncoding RNA, acts as novel oncogene in regulating cancer cell growth in colorectal cancer. Mol
    Cancer. 2018 Mar 10;17(1):72.
    36. Wu SM*, Liu H*, Huang PJ, Chang IY, Lee CC, Yang CY, Tsai WS, Tan BC. circlncRNAnet: an
    integrated web-based resource for mapping functional networks of long or circular forms of noncoding
    RNAs. Gigascience. 2018 Jan 1;7(1):1-10. (First author)
    37. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, Tan BC. MiR-31-5p-ACOX1
    Axis Enhances Tumorigenic Fitness in Oral Squamous Cell Carcinoma Via the Promigratory
    Prostaglandin E2. Theranostics. 2018 Jan 1;8(2):486-504.
    38. Chen TW*, Lee CC*, Liu H*, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD,
    Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW,
    See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS.
    APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion
    polymorphism. Nat Commun. 2017 Sep 6;8(1):465. (First author) (IF:15.7, 7/136
    MULTIDISCIPLINARY SCIENCES)
    39. Yang CC, Chen YT, Chang YF, Liu H, Kuo YP, Shih CT, Liao WC, Chen HW, Tsai WS, Tan BC.
    ADAR1-mediated 3' UTR editing and expression control of antiapoptosis genes fine-tunes cellular
    apoptosis response. Cell Death Dis. 2017 May 25;8(5): e2833.
    40. Chen H, Hsiao YC, Chiang SF, Wu CC, Lin YT, Liu H, Zhao H, Chen JS, Chang YS, Yu JS.
    Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using
    immunoenrichment and targeted mass spectrometry. Anal Chim Acta. 2016 Aug 24;933: 144-55. doi:
    10.1016/j.aca.2016.05.037. Epub 2016 Jun 2. IF: 6.911, RANK: 10/87 CHEMISTRY, ANALYTICAL.
    41. Yang XZ, Chen JY, Liu CJ, Peng J, Wee YR, Han X, Wang C, Zhong X, Shen QS, Liu H, Cao H, Chen
    XW, Tan BC, Li CY. Selectively Constrained RNA Editing Regulation Crosstalks with piRNA
    Biogenesis in Primates. Mol Biol Evol. 2015 Dec;32(12):3143-57.
    42. Chen WY, Shih HT, Liu KY, Shih ZS, Chen LK, Tsai TH, Chen MJ, Liu H, Tan BC, Chen CY, Lee HH,
    Loppin B, Aït-Ahmed O, Wu JT. Intellectual disability-associated dBRWD3 regulates gene expression
    through inhibition of HIRA/YEM-mediated chromatin deposition of histone H3.3. EMBO Rep. 2015
    Apr;16(4):528-38.
    43. Huang PJ, Lee CC, Tan BC, Yeh YM, Huang KY, Gan RC, Chen TW, Lee CY, Yang ST, Liao CS, Liu
    H*, Tang P*. Vanno: a visualization-aided variant annotation tool. Hum Mutat. 2015 Feb;36(2):167-74.
    (Corresponding author)
    44. Huang PJ, Lee CC, Tan BC, Yeh YM, Julie Chu L, Chen TW, Chang KP, Lee CY, Gan RC, Liu H*, Tang
    P*. CMPD: cancer mutant proteome database. Nucleic Acids Res. 2015 Jan;43(Database issue): D849-55. (Corresponding author)
    45. Liu H, Ma CP, Chen YT, Schuyler SC, Chang KP, Tan BC. Functional Impact of RNA editing and
    ADARs on regulation of gene expression: perspectives from deep sequencing studies. Cell Biosci. 2014
    Aug 19;4: 44. (First author)
    46. Liu YC, Kuo RL, Lin JY, Huang PN, Huang Y, Liu H, Arnold JJ, Chen SJ, Wang RY, Cameron CE, Shih
    SR. Cytoplasmic viral RNA-dependent RNA polymerase disrupts the intracellular splicing machinery by
    entering the nucleus and interfering with Prp8. PLoS Pathog. 2014 Jun 26;10(6): e1004199.
    47. C-L Hsieh, Liu H, Y Huang, L Kang, H-W Chen, Y-T Chen, Y-R Wee, S-J Chen, B C-M Tan. ADAR1
    deaminase contributes to scheduled skeletal myogenesis progression via stage-specific functions. Cell
    Death Differ. 2014 May;21(5):707-19.
    48. Chen HW, Yang CC, Hsieh CL, Liu H, Lee SC, Tan BC. A functional genomic approach reveals the
    transcriptional role of EDD in the expression and function of angiogenesis regulator ACVRL1. Biochim
    Biophys Acta. 2013 Dec;1829(12):1309-19.
    49. Huang PJ, Yeh YM, Gan RC, Lee CC, Chen TW, Lee CY, Liu H, Chen SJ, Tang P. CPAP. Cancer Panel
    Analysis Pipeline. Hum Mutat. 2013 Oct;34(10):1340-6.
    50. Lo SJ, Fan LC, Tsai YF, Lin KY, Huang HL, Wang TH, Liu H, Chen TC, Huang SF, Chang CJ, Lin YJ,
    Yung BY, Hsieh SY. A novel interaction of nucleophosmin with BCL2-associated X protein regulating
    death evasion and drug sensitivity in human hepatoma cells. Hepatology. 2013 May;57(5):1893-905.
    51. Tan BC, Yang CC, Hsieh CL, Chou YH, Zhong CZ, Yung BY, Liu H. Epigeneitc silencing of ribosomal
    RNA genes by Mybbp1a. J Biomed Sci. 2012 Jun 11;19(1):57. (Corresponding author)
    52. Yang CC*, Liu H*, Chen SL, Wang TH, Hsieh CL, Huang Y, Chen SJ, Chen HC, Yung BY, Chin-Ming
    Tan B. Epigenetic silencing of myogenic gene program by Myb-binding protein 1a suppresses
    myogenesis. EMBO J. 2012 Apr 4;31(7):1739-51. (First author)
    53. Lin CY, Tan BC, Liu H, Shih CJ, Chien KY, Lin CL, Yung BY. WDHD1 modulates the post-
    transcriptional step of the centromeric silencing pathway. Nucleic Acids Res. 2011 May;39(10):4048-62.
    54. Lin CY, Tan BC, Liu H, Shih CJ, Chien KY, Lin CL, Yung BY. Dephosphorylation of nucleophosmin by
    PP1beta facilitates pRB binding and consequent E2F1-dependent DNA repair. Mol Biol Cell. 2010
    Dec;21(24):4409-17.
    55. Tan BC*, Liu H*, Lin CL, Lee SC. Functional cooperation between FACT and MCM is coordinated
    with cell cycle and differential complex formation. J Biomed Sci. 2010 Feb 16;17(1):11. (First author)
    56. Liu H, Tan BC, Tseng KH, Chuang CP, Yeh CW, Chen KD, Lee SC, Yung BY. Nucleophosmin acts as a
    novel AP2alpha-binding transcriptional corepressor during cell differentiation. EMBO Rep. 2007
    Apr;8(4):394-400. (First author)
    57. Chen SH, Wu PS, Chou CH, Yan YT, Liu H, Weng SY, Yang-Yen HF. A knockout mouse approach
    reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell
    type-specific manner. Mol Biol Cell. 2007 Jul;18(7):2525-32.
    58. Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF. Stabilization and enhancement of the
    antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol. 2005 Apr;25(8):3117-26. (First author)

Patents and Technology Transfer

  • Republic of China Invention Patent No. I661198
    Inventors: Hsien-Ming Tan, Hsuan Liu, and Yi-Hsuan Lai
    Assignee: Chang Gung University
    Title: Method for Making Diagnosis of Human Oral Cancer
    Patent Period: June 1, 2019 – January 25, 2038
  • Republic of China Invention Patent No. I666449
    Inventors: Hsien-Ming Tan, Hsuan Liu, and Yi-Hsuan Lai
    Assignee: Chang Gung University
    Title: Method for Making Diagnosis of Human Oral Cancer
    Patent Period: July 21, 2019 – January 25, 2038
  • Hong Kong Invention Patent No. HK40010644
    Inventors: Hsien-Ming Tan, Hsuan Liu, and Yi-Hsuan Lai
    Assignee: Chang Gung University
    Title: Systems and Uses for Making Diagnosis and/or Prognosis of Human Oral Cancer
    Patent Period: February 17, 2023 – January 16, 2039